Published in
American Society of Hematology, Blood, 22(130), p. 2401-2409, 2017
DOI: 10.1182/blood-2017-06-788786
Links
Tools
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Journal article published in 2017 by
Shaji Kumar 
,
Jonathan L. Kaufman,
Cristina Gasparetto,
Joseph Mikhael,
Ravi Vij,
Brigitte Pegourie,
Lofti Benboubker,
Thierry Facon,
Martine Amiot ,
Philippe Moreau,
Elizabeth A. Punnoose,
Stefanie Alzate,
Martin Dunbar,
Tu Xu,
Suresh K. Agarwal
and other authors.
,
Jonathan L. Kaufman,
Cristina Gasparetto,
Joseph Mikhael,
Ravi Vij,
Brigitte Pegourie,
Lofti Benboubker,
Thierry Facon,
Martine Amiot ,
Philippe Moreau,
Elizabeth A. Punnoose,
Stefanie Alzate,
Martin Dunbar,
Tu Xu,
Suresh K. Agarwal
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profile in patients with relapsed/refractory MM. Venetoclax monotherapy has demonstrated antimyeloma activity in patients with relapsed/refractory MM positive for t(11;14).